Dr. Natalia Novac is the Director of Emerging Technologies and Innovation Group in Corporate Business Development of Eli Lilly and is responsible for search and evaluation of novel healthcare technologies across five indications of Eli Lilly: oncology, immunology, diabetes and complications, neurodegenerative diseases and pain. Emerging technology and innovation is particularly focused on First-in-Class Opportunities such as innovative cross-functional enabling technologies, novel targets and modalities, untapped modes of action. Natalia is based in London and is responsible for novel in-licensing opportunities in Europe. . Background: 15 years in pharmaceutical industry with solid background in oncology, endocrinology and immunology. Natalia has a PhD in Molecular Biology, from the Karlsruhe Institute of Technology, Germany and MSc in Microbiology from the University of Warwick, UK.